New Managed Care Study Results Reported from Yale University School of Medicine (Association of Social Determinants of Health with Utilization of SGLT2 Inhibitors and GLP1 Receptor Agonists: A Systematic Review and Meta-Analysis): Managed Care

2026 MAR 27 (NewsRx) -- By a News Reporter-Staff News Editor at Education Daily Report -- Fresh data on Managed Care are presented in a new report. According to news reporting originating from New Haven, Connecticut, by NewsRx correspondents, research stated, “SGLT2 inhibitors (SGLT2i) and GLP-1 receptor agonists (GLP-1RA) reduce cardiovascular and metabolic risks in type-2 diabetes, cardiovascular disease, and obesity, yet social determinants of health (SDOH) may influence access to these therapies. We conducted a systematic review and meta-analysis to assess whether SDOH-socioeconomic status (SES), insurance status, education, geography, neighborhood deprivation-and demographic characteristics-race and sex-are associated with differential utilization of SGLT2i or GLP-1RA.”

Our news editors obtained a quote from the research from the Yale University School of Medicine, “Six databases (Ovid MEDLINE, Ovid Embase, Scopus, Web of Science, Cochrane Library, and Google Scholar) were searched through February 2025. Retrospective and cross-sectional studies reporting association between at least one SDOH and prescription of SGLT2i and/or GLP-1RA were included. The primary outcome was the adjusted odds of utilization of SGLT2i, GLP-1RA, or both drugs by SDOH categories. Meta-analyses were conducted separately for SGLT2i and GLP-1RA using random-effects models. Risk of bias was assessed using ROBINS-I. Twenty-six studies (> 14.6 million patients) were included. Low-SES patients had reduced odds of utilization (aOR 0.73; 95% CI 0.61-0.76). Medicaid (aOR 0.70; 95% CI 0.55-0.89), Medicare (0.68; 0.60-0.78), and Medicare Advantage (aOR 0.41; 95% CI 0.30-0.57) patients had lower odds than privately insured patients. Lower educational attainment (aOR 0.70; 95% CI 0.53-0.93) and rurality (aOR 0.91; 95% CI 0.87-0.95) were associated with reduced utilization. Patients in high-deprivation neighborhoods (aOR 0.80; 95% CI 0.69-0.93) had lower odds of GLP-1RA utilization. Women had lower odds of SGLT2i utilization (aOR 0.89; 95% CI 0.82-0.95), but greater odds of GLP-1RA (aOR 1.33, 1.23-1.43). Black (aOR 0.80; 95% CI 0.79-0.82) patients had reduced utilization of both drugs, while Hispanic (aOR 0.81; 95% CI 0.69-0.96), and Asian (aOR 0.49; 95% CI 0.41-0.58) patients had reduced odds of GLP-1RA.”

According to the news editors, the research concluded: “Disparities in SGLT2i and GLP-1RA utilization span SES, insurance, education, geography, neighborhood deprivation, race, and sex, potentially limiting population-level benefits and warranting interventions to improve access.”

This research has been peer-reviewed.

For more information on this research see: Association of Social Determinants of Health with Utilization of SGLT2 Inhibitors and GLP1 Receptor Agonists: A Systematic Review and Meta-Analysis. Journal of General Internal Medicine, 2026. Journal of General Internal Medicine can be contacted at: Springer, One New York Plaza, Suite 4600, New York, Ny, United States. (Wiley-Blackwell - http://www.wiley.com/; Journal of General Internal Medicine - http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1525-1497)

The news editors report that additional information may be obtained by contacting Nisarg Shah, Yale University School of Medicine, New Haven, CT, United States. Additional authors for this research include Johann Alexandre Chafa Edjimbi, Melissa Daou, Alyssa A. Grimshaw, Craig Gunderson and Shaili Gupta.

Publisher contact information for the Journal of General Internal Medicine is: Springer, One New York Plaza, Suite 4600, New York, Ny, United States.

(Our reports deliver fact-based news of research and discoveries from around the world.)